ProCE Banner Activity

Phase II REACH1: Ruxolitinib + Corticosteroids in Steroid-Refractory Acute Graft-vs-Host Disease

Slideset Download
Conference Coverage
Rapid and durable responses to the selective JAK1/JAK2 inhibitor ruxolitinib plus corticosteroids were observed across all patient subgroups defined by baseline steroid-refractory criteria, organ involvement, and disease stage.

Released: December 12, 2018

Expiration: December 11, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology